Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK7 | Q13164 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008489 | 0.90 | PPARG (0.51) | PPARGMEN1KMT2A | |
| SCHEMBL5010405 | 0.90 | PPARG (0.59) | PPARG | |
| SCHEMBL5013662 | 0.90 | PPARG (0.48) | PPARGSMN1; SMN2KMT2A | |
| SCHEMBL14587671 | 0.90 | SMN1; SMN2 (0.48) | NAMPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5010420 | 0.89 | PPARG (0.47) | PPARGHTTSORT1 | |
| SCHEMBL5010706 | 0.88 | PPARG (0.47) | PPARGHTT | |
| SCHEMBL5013431 | 0.88 | NPC1 (0.49) | PPARGSMN1; SMN2 | |
| SCHEMBL5010627 | 0.88 | PPARG (0.47) | PPARG | |
| SCHEMBL5012182 | 0.88 | PPARG (0.56) | PPARG | |
| SCHEMBL14298461 | 0.88 | GAA (0.53) | PPARGNAMPTHTTSORT1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | PPARG 706/4885NAMPT 2652/4885HSD17B10 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.